Dendreon (DNDN) 10-Q 11 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 04, 2014
Document And Entity Information [Abstract]	'	'
Entity Registrant Name	'DENDREON CORP	'
Entity Central Index Key	'0001107332	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	160,314,362

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$66,921	$92,530
Short-term investments	60,376	87,092
Trade accounts receivable	30,306	34,560
Inventory	70,031	54,346
Prepaid expenses and other current assets	8,893	15,220
Total current assets	236,527	283,748
Property and equipment, net	113,456	125,168
Long-term investments	9,425	19,819
Other assets	5,221	5,666
Total assets	364,629	434,401
Current liabilities:	'	'
Accounts payable	13,939	10,459
Accrued liabilities	35,930	33,619
Accrued compensation	15,705	20,144
Restructuring, contract termination and advisory liabilities	4,997	8,793
Current portion of convertible debt	'	27,685
Current portion of capital lease obligations	2,436	2,429
Current portion of facility lease obligations	657	632
Total current liabilities	73,664	103,761
Long-term accrued liabilities	5,630	5,471
Capital lease obligations, less current portion	2,255	3,575
Facility lease obligations, less current portion	9,754	10,123
Convertible senior notes due 2016, net of discount	573,135	559,122
Commitments and contingencies (Note 13)	'	'
Stockholders' deficit:	'	'
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding	'	'
Common stock, $0.001 par value; 250,000,000 shares authorized, 160,098,163 and 157,274,622 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	154	153
Additional paid-in capital	2,002,805	2,003,271
Accumulated other comprehensive income	39	79
Accumulated deficit	-2,302,807	-2,251,154
Total stockholders' deficit	-299,809	-247,651
Total liabilities and stockholders' deficit	$364,629	$434,401

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Stockholders' deficit:	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	160,098,163	157,274,622
Common stock, shares outstanding	160,098,163	157,274,622

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Consolidated Statements Of Operations [Abstract]	'	'	'	'
Product revenue, net	$82,163	$73,286	$150,943	$140,866
Royalty and other revenue	48	29	48	43
Total revenue	82,211	73,315	150,991	140,909
Operating expenses:	'	'	'	'
Cost of product revenue	37,871	43,798	74,500	87,173
Inventory insurance recovery	-15,566	'	-15,566	'
Research and development	13,577	18,163	27,572	36,611
Selling, general and administrative	44,939	66,831	84,328	129,277
Restructuring, contract termination and advisory costs	3,059	-304	4,905	1,656
Total operating expenses	83,880	128,488	175,739	254,717
Loss from operations	-1,669	-55,173	-24,748	-113,808
Other income (expense):	'	'	'	'
Interest income	52	177	136	395
Interest expense	-13,647	-13,886	-27,073	-27,515
Other income	-5	40	32	81
Net loss	($15,269)	($68,842)	($51,653)	($140,847)
Basic and diluted net loss per share	($0.10)	($0.45)	($0.34)	($0.93)
Shares used in computation of basic and diluted net loss per share	154,038	151,812	153,830	151,647

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Consolidated Statements Of Comprehensive Loss [Abstract]	'	'	'	'
Net loss	($15,269)	($68,842)	($51,653)	($140,847)
Other comprehensive loss:	'	'	'	'
Net unrealized loss on securities	-14	-106	-40	-162
Comprehensive loss	($15,283)	($68,948)	($51,693)	($141,009)

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Operating Activities:	'	'
Net loss	($51,653)	($140,847)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation expense	12,535	15,721
Non-cash stock-based compensation expense (contra expense)	-377	5,494
Amortization of securities discount and premium	622	1,435
Amortization of convertible notes discount and debt issuance costs	15,119	13,987
Other	157	268
Changes in operating assets and liabilities:	'	'
Trade accounts receivable	4,254	2,332
Inventory	-9,570	-13,700
Prepaid expenses and other assets	-454	-5,354
Accounts payable	3,480	-5,224
Accrued liabilities and compensation	-2,128	-4,815
Restructuring, contract termination and advisory liabilities	-3,796	-8,606
Net cash used in operating activities	-31,811	-139,309
Investing Activities:	'	'
Maturities and sales of investments	44,481	110,110
Purchases of investments	-8,029	-58,886
Purchases of property and equipment	-820	-5,121
Net cash provided by investing activities	35,632	46,103
Financing Activities:	'	'
Payment of convertible senior subordinated notes	-27,685	'
Payments on facility lease obligations	-344	-335
Payments on capital lease obligations	-1,313	-3,179
Proceeds from deposits	'	87
Issuance of common stock under the Employee Stock Purchase Plan	397	1,006
Net proceeds from the exercise of stock options	'	41
Other	-485	-810
Net cash used in financing activities	-29,430	-3,190
Net decrease in cash and cash equivalents	-25,609	-96,396
Cash and cash equivalents at beginning of period	92,530	188,408
Cash and cash equivalents at end of period	66,921	92,012
Supplemental Disclosure of Cash Flow Information:	'	'
Cash paid during the period for interest	11,811	13,745
Inventory insurance cash received	$15,566	'

Business_Principles_Of_Consoli

Business, Principles Of Consolidation And Basis Of Presentation	6 Months Ended
	Jun. 30, 2014
Business, Principles Of Consolidation And Basis Of Presentation [Abstract]	'
Business, Principles Of Consolidation And Basis Of Presentation	'
	DENDREON CORPORATION
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
	(Unaudited)
	1. BUSINESS, PRINCIPLES OF CONSOLIDATION AND BASIS OF PRESENTATION
	Business
	Dendreon Corporation (referred to as “Dendreon,” the “Company,” “we,” “us,” or “our”), a Delaware corporation, is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. Our product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers.
	PROVENGE® (sipuleucel-T), is our first commercialized product approved by the United States Food and Drug Administration, and is a first-in-class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Commercial sale of PROVENGE began in May 2010. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second leading cause of cancer deaths in men in the United States. We own worldwide rights for PROVENGE.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Dendreon and its direct and indirect wholly-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation.
	Basis of Presentation
	The accompanying unaudited financial statements reflect, in the opinion of management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations and cash flows for each period presented in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from the accompanying statements. These interim financial statements should be read in conjunction with the audited financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2013 (the “2013 Form 10-K”). The accompanying financial information as of December 31, 2013 has been derived from the audited 2013 consolidated financial statements included in the 2013 Form 10-K. Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of results that may be expected for the year ending December 31, 2014, or any other future period.
	Liquidity Risks and Uncertainties
	Our 2016 Notes, as discussed in Note 10 below, have an aggregate principal amount of $620 million and mature on January 15, 2016. Our stock price is well below the $51.24 effective conversion price for the 2016 Notes, making it unlikely that the holders of the 2016 Notes will exercise their conversion right. As a result, we assume that, absent the execution of a transaction of the type described below, we will be required under the terms of the 2016 Notes to repay the full $620 million principal amount at maturity. Based on our currently anticipated operating results, however, and even assuming the realization of future expense reductions that we plan to make and product revenues that we forecast, there is a significant risk that, while we believe we have sufficient cash to meet our ordinary course obligations for at least the next twelve months, we will not be able to repay or refinance the 2016 Notes. Accordingly, we are currently considering alternatives to the repayment of the 2016 Notes in cash, including alternatives that could result in leaving our current stockholders with little or no financial ownership of Dendreon. Our Board of Directors will consider any strategic alternatives that might be presented by third parties, though there can be no guarantee that any such alternative will provide value for the Company’s stockholders.
	In addition, our business and operations are subject to various risks relating to our financial condition, some of which could result from concerns our stakeholders may have about our financial situation and others that could result if we were to pursue alternatives to the repayment of the 2016 Notes in cash.  These risks include, but are not limited to, the following:
		·	certain of our suppliers may attempt to cancel our contracts or restrict ordinary credit terms, require financial assurances of performance or refrain entirely from providing goods or services to us;
		·	our employees may become distracted from performance of their duties;
		·	physicians could cease to purchase and prescribe PROVENGE;
		·	we may have difficulty continuing to obtain and maintain contracts necessary to continue our operations and at affordable rates with competitive terms;
		·	we may have difficulty maintaining existing and building new relationships;
		·	and we may be unable to retain and motivate key executives and employees and we may have difficulty attracting new employees.
	As of June 30, 2014, our accumulated deficit was $2.3 billion and our net loss for six months ended June 30, 2014 was $51.7 million. We have incurred net losses as a result of research and development expenses, clinical trial expenses, contract manufacturing and facility expenses, costs associated with our commercial efforts on behalf of PROVENGE and general and administrative expenses in support of our operations and research efforts. The majority of our resources continue to be used in support of the commercialization of PROVENGE, including outside the United States. Even if we are able to successfully realize our current operating projections, we will likely be unable to repay or refinance the 2016 Notes when they mature. And in any event, we are unable to predict when our core business will break-even or become profitable, if at all. Even if we do produce revenues and achieve profitability, we may not be able to maintain or increase profitability, and our current stockholders may be left with little or no financial interest at such time.
	Use of Estimates
	Our financial statements have been prepared in accordance with GAAP.  The preparation of these financial statements requires us to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, inventory, investments, fair values of assets, incurred but not reported medical insurance claims, income taxes, financing activities, accruals and other contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates.

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Summary Of Significant Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Revenue Recognition
	We recognize revenue primarily from the sale of PROVENGE. Revenue from the sale of PROVENGE is recorded net of product returns and estimated price discounts, including rebates and chargebacks offered pursuant to mandatory federal and state government programs and to members of Group Purchasing Organizations (“GPOs”) with which we have contracts. Revenue from sales of PROVENGE is recognized upon confirmed product delivery to and issuance of a product release form to the physician. Product returns are limited to those instances in which the physician receives the product but does not infuse the product prior to expiry, either due to timing or the failure of the product to meet specifications and pass site inspection. Due to the limited usable life of PROVENGE of approximately 18 hours from the completion of the manufacturing process to patient infusion, actual return information is known and credited against sales in the month incurred.
	PROVENGE sales are direct to physician; however, we have entered into distribution agreements with several credit-worthy third-party wholesalers (the “Wholesalers”) whereby we manufacture and ship the product direct to the physician and transfer the sale of PROVENGE to the Wholesalers. Under the distribution agreements, the Wholesalers assume all bad debt risk from the physician or institution; therefore no allowance for bad debt is recorded. Under the terms of the distribution agreements, our return policy allows for the return of product that has expired or has a defect prior to delivery, product that is damaged during delivery and product that cannot be infused because it does not otherwise meet specified requirements.
	Our product is subject to certain required pricing discounts via rebates and/or chargebacks pursuant to mandatory federal and state government programs and, accordingly, revenue recognition requires estimates of rebates and chargebacks.
	We have agreements with the Centers for Medicare and Medicaid Services (“CMS”) providing for a rebate on sales to eligible Medicaid patients. The physician purchases our product at full price, and then receives reimbursement from the applicable state. The state, in turn, invoices us for the amount of the Medicaid rebate. Estimated rebates payable under Medicaid are recognized in the same period that the related revenue is recognized, resulting in a reduction in product revenue, and are classified as other accrued liabilities until paid. Our estimate of rebates payable is based on historical claim information. Medicaid rebates were not material for each period presented.
	We also have agreements with the Public Health Service (“PHS”) and Federal Supply Schedule (“FSS”) customers, including the Department of Veteran Affairs and the Department of Defense, providing for a chargeback on sales to eligible providers. Chargebacks occur when a contracted physician purchases our product at fixed contract prices that are lower than the price we charge the Wholesalers. Each Wholesaler, in turn, charges us back for the difference between the price initially paid by the Wholesaler and the contract price paid to the Wholesaler by the physician. These chargebacks are estimated and recorded in the period that the related revenue is recognized, resulting in a reduction in product revenue and trade accounts receivable. The following is a roll forward of the chargebacks reserve associated with the PHS and FSS programs:
		Six Months Ended June 30,
		2014		2013
		(In thousands)
	Beginning balance, January 1	$	3,540	$	3,107
	Current provision related to sales made in current period		9,469		6,588
	Adjustments		-1,064		-1,575
	Payments/credits		-7,544		-5,425
	Balance at June 30	$	4,401	$	2,695
	We have entered into agreements with certain GPOs that contract for the purchase of PROVENGE on behalf of their members and provide contract administration services. Eligible members of the GPOs purchase PROVENGE at contracted prices through a chargeback. These chargebacks are estimated and recorded in the period that the related revenue is recognized, resulting in a reduction in product revenue and trade accounts receivable. The following is a roll forward of the chargebacks reserve associated with the GPO programs:
		Six Months Ended June 30,
		2014		2013
		(In thousands)
	Beginning balance, January 1	$	1,590	$	182
	Current provision related to sales made in current period		8,932		2,835
	Current provision related to sales made in prior periods		7		—
	Payments/credits		-9,200		-2,659
	Balance at June 30	$	1,329	$	358
	Eligible members of the GPOs may also be entitled to receive a rebate on eligible purchases of PROVENGE at the end of each quarter. Estimated rebates and administrative fees payable to GPOs are recognized in the same period that the related revenue is recognized, resulting in a reduction in product revenue, and are classified as other accrued liabilities until paid. Our estimate of rebates payable is based upon information we gather related to sales to eligible GPO members. The following is a roll forward of the accrued GPO rebates and administrative fees balance:
		Six Months Ended June 30,
		2014		2013
		(In thousands)
	Beginning balance, January 1	$	1,788	$	1,950
	Current provision related to sales made in current period		4,139		3,098
	Payments/credits		-3,518		-3,435
	Balance at June 30	$	2,409	$	1,613
	Inventory
	Inventories are determined at the lower of cost or market value with cost determined under the specific identification method.
	We periodically evaluate our inventory for impairment by considering factors such as expiry, obsolescence and net realizable value. We review inventory for expiry risk by evaluating current and future product demand relative to inventory life. We expect to realize the carrying value of our inventory.
	In addition, we evaluate our inventory for impairment when events and circumstances indicate that our inventory may not meet the quality specifications required to be used in commercial production. If we determine it is likely that inventory does not meet quality specifications, we record an impairment of this inventory.
	Restructuring Expenses
	We record a liability for costs associated with an exit or disposal activity at fair value in the period in which the liability is incurred.  Employee termination benefits are accrued when the obligation is probable and estimable. Employee termination benefits are expensed at the date the employee is notified unless the employee must provide future service in excess of 60 days, in which case such benefits are expensed ratably over the future service period. For contract termination costs, we record a liability upon the later of the contract termination date or the date we cease using the rights conveyed by the contract.
	Impairment of Long-Lived Assets
	We periodically evaluate the carrying value of long-lived assets to be held and used when events and circumstances indicate that the carrying amount of an asset may not be recovered. When evaluating long-lived assets for impairment, we compare the carrying value of the asset to the asset's estimated undiscounted future cash flows. Impairment is recorded if the estimated future cash flows are less than the carrying value of the asset. The impairment loss recognized, if any, is the excess of the asset’s carrying value over the fair value of the long-lived asset. The determination of fair value of the assets evaluated for impairment requires the use of judgmental assumptions surrounding the amount and timing of future cash flows and the highest and best use of the assets.
	Accounting for Stock-Based Compensation
	Stock-based compensation cost is estimated at the grant date based on the award’s fair value and is recognized on the accelerated method as expense over the requisite service period. The fair value of stock options granted and stock issued under the Employee Stock Purchase Plan is calculated using the Black-Scholes-Merton (“BSM”) option pricing model. The BSM model requires various judgmental assumptions regarding volatility and expected option life. If any of the assumptions used in the BSM model change significantly, stock-based compensation expense for new awards may differ materially from that recorded for existing awards.
	Restricted stock awards generally vest and are expensed over two- to four-year periods. We have granted restricted stock awards and options with certain performance conditions to certain executive officers and key employees. At each reporting date, we evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon our assessment of accomplishing each performance provision or the occurrence of other events which may have caused the awards or options to accelerate and vest.
	In the second quarter of 2013, we granted cash-settled stock appreciation rights with a two-year vest period to certain employees. These awards are classified as liabilities and are measured at fair value at each reporting date, with fair value being determined using the BSM model.
	Stock-based compensation accounting also requires the estimate of forfeiture rates. In the first and second quarters of 2014 and 2013, we increased our estimated forfeiture rates based on historical data, resulting in cumulative catch-up adjustments to decrease stock-based compensation expense and net loss by $3.6 million and $5.8 million for the six months ended June 30, 2014 and 2013, respectively. These adjustments decreased basic and diluted net loss per share by $0.02 and $0.04 for the six months ended June 30, 2014 and 2013, respectively.
	Net Loss Per Share
	Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding. The calculation of diluted net loss per share excludes all outstanding stock options, unvested restricted stock and shares issuable upon potential conversion of the 2.875% Convertible Senior Notes due 2016 (the “2016 Notes”) in the three and six months ended June 30, 2014 and 2013 and the 4.75% Convertible Senior Subordinated Notes due 2014 (the “2014 Notes”) in the three and six months ended June 30, 2013 because all such securities are anti-dilutive: accordingly, diluted net loss per shares is the same as basic net loss per share. For the three and six months ended June 30, 2014 and 2013, the computation of diluted net loss per share excluded 19.1 million shares and 23.3 million shares, respectively.
	Comprehensive Loss
	Comprehensive loss includes charges and credits to stockholders’ deficit that are not the result of transactions with stockholders. Comprehensive loss consisted of net loss plus changes in unrealized gain or loss on investments for the three and six months ended June 30, 2014 and 2013.
	Loss Contingencies
	A loss contingency is recorded if it is probable that an asset has been impaired or a liability has been incurred and the amount of the loss can be reasonably estimated. We evaluate, among other factors, the probability of an unfavorable outcome and our ability to reasonably estimate the amount of the ultimate loss. Loss contingencies that we determine to be reasonably possible, but not probable, are disclosed but not recorded. Changes in these estimates could materially affect our financial position and results of operations.
	Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update 2013-11 (“ASU 2013-11”), “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” This standard requires that an unrecognized tax benefit, or a portion of an unrecognized tax benefit be presented as a reduction of a deferred tax asset for an NOL carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions to this rule. If certain exception conditions exist, an entity should present an unrecognized tax benefit in the financial statements as a liability and should not net the unrecognized tax benefit with a deferred tax asset.  The adoption of ASU 2013-11 on January 1, 2014 did not have a material impact on our financial position, results of operations or cash flows.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers,” which supersedes the guidance in “Revenue Recognition (Topic 605)” and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. We are evaluating the new standard, but do not at this time expect this standard to have a material impact on our consolidated financial statements.
	For a more detailed listing of our significant accounting policies, see Note 2 of the consolidated financial statements included in the 2013 Form 10-K.

Investments

Investments	6 Months Ended
	Jun. 30, 2014
Investments [Abstract]	'
Investments	'
	3. INVESTMENTS
	Securities available-for-sale at cost or amortized cost and fair market value by contractual maturity were as follows:
		Cost or Amortized Cost		Fair Market Value
		(In thousands)
	June 30, 2014
	Due in one year or less	$	60,343	$	60,376
	Due after one year through two years		9,419		9,425
		$	69,762	$	69,801
	December 31, 2013
	Due in one year or less	$	87,027	$	87,092
	Due after one year through two years		19,805		19,819
		$	106,832	$	106,911
	Gross realized gains and losses on sales of available-for-sale securities were not material for the three and six months ended June 30, 2014 and 2013.
	Securities available-for-sale, short-term and long-term, consisted of the following:
		Cost or Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Market Value
		(In thousands)
	June 30, 2014
	Demand deposit	$	5,404	$	—	$	—	$	5,404
	Corporate debt securities		45,947		34		-1		45,980
	Government-sponsored enterprises		14,911		3		—		14,914
	U.S. Treasury notes		3,500		3		—		3,503
		$	69,762	$	40	$	-1	$	69,801
	December 31, 2013
	Demand deposit	$	5,404	$	—	$	—	$	5,404
	Corporate debt securities		64,867		59		-4		64,922
	Government-sponsored enterprises		13,064		12		—		13,076
	U.S. Treasury notes		23,497		12		—		23,509
		$	106,832	$	83	$	-4	$	106,911
	None of the securities have been in a continuous unrealized loss position for more than 12 months as of June 30, 2014.
	Market values were determined for each individual security in the investment portfolio. We utilize third-party pricing services for all security valuations. We review the pricing methodology, including the collection of market information, used by the third-party pricing services. On a periodic basis, we also review and validate the pricing information received from the third-party providers.
	The declines in value of these investments are primarily related to changes in interest rates and are considered to be temporary in nature. We evaluate, among other things, the duration and extent to which the fair value of a security is less than its cost, the financial condition of the issuer, and our intent to sell, or whether it is more likely than not that we will be required to sell the security before recovery of the amortized cost basis. We have the ability and intent to hold these securities to maturity; therefore we do not consider these investments to be other-than-temporarily impaired as of June 30, 2014. Refer to Note 4 – Fair Value Measurements for further discussion.
	Investments securing letters of credit in the aggregate amount of $5.4 million as of June 30, 2014 and December 31, 2013 are classified as long-term investments.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	4. FAIR VALUE MEASUREMENTS
	We measure and report at fair value cash equivalents and investment securities (financial assets). Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The hierarchy of fair value measurements is described below:
	Level 1 —  Observable inputs for identical assets or liabilities such as quoted prices in active markets,
	Level 2 — Inputs other than quoted prices in active markets that are either directly or indirectly observable, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs), and
	Level 3 — Unobservable inputs in which little or no market data exists, therefore determined using estimates and assumptions developed by us, which reflect those that a market participant would use.
	The following summarizes financial assets measured at fair value on a recurring basis:
	Description	Balance		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)
	Assets:	(In thousands)
	June 30, 2014
	Money market	$	61,901	$	61,901	$	—
	Corporate debt securities		45,980		—		45,980
	Government-sponsored enterprises		14,914		—		14,914
	U.S. Treasury notes		3,503		—		3,503
	Total financial assets		126,298	$	61,901	$	64,397
	Add: Cash		10,424
	Total cash, cash equivalents and investments	$	136,722
	December 31, 2013
	Money market	$	68,534	$	68,534	$	—
	Commercial paper		6,000		—		6,000
	Corporate debt securities		64,922		—		64,922
	Government-sponsored enterprises		13,076		—		13,076
	U.S. Treasury notes		23,509		—		23,509
	Total financial assets		176,041	$	68,534	$	107,507
	Add: Cash		23,400
	Total cash, cash equivalents and investments	$	199,441
	Fixed income investment securities are valued using the market approach. We had no Level 3 financial assets for either period presented.
	The fair value of the 2016 Notes as of June 30, 2014 and December 31, 2013 was approximately $427.8 million and $393.8 million, respectively, based on the last trading prices as of the respective period end. The fair value estimate for the 2016 Notes is based on Level 2 inputs.
	The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to their short-term nature. In addition, our capital lease obligations approximate fair value based on current interest rates, which contain an element of default risk.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2014
Inventory [Abstract]	'
Inventory	'
	5. INVENTORY
	Inventories, stated at the lower of cost or market, consisted of raw materials of $70.0 million as of June 30, 2014 and $54.3 million as of December 31, 2013. Raw materials inventory is expected to be used over approximately 2.6 years as of June 30, 2014.
	During the year ended December 31, 2013, we recorded a charge of $46.2 million related to antigen inventory which no longer met quality specification and was not usable for commercial production, or which was determined to be likely to fail such quality specification. We have insurance coverage for up to $30.0 million for antigen losses of the type we believe we have sustained. We have filed an insurance claim to seek recovery for these losses. As of June 30, 2014, we have received $15.6 million in insurance proceeds related to this inventory claim and are pursuing the remaining reimbursement from our insurance carrier. The $15.6 million recovery is included in “Inventory insurance recovery” on our consolidated statement of operations. Reimbursement of the remaining $14.4 million cannot be assured with certainty at this time. We believe no other antigen inventory was at risk of being out of quality specification at June 30, 2014.

Prepaid_Expenses_And_Other_Cur

Prepaid Expenses And Other Current Assets	6 Months Ended
	Jun. 30, 2014
Prepaid Expenses And Other Current Assets [Abstract]	'
Prepaid Expenses And Other Current Assets	'
	6. PREPAID EXPENSES AND OTHER CURRENT ASSETS
	As of December 31, 2013, there was $5.9 million included in “Prepaid expenses and other current assets” on the consolidated balance sheet related to costs associated with agreements to develop second source suppliers for materials used in the manufacture of PROVENGE, and to qualify a contract manufacturer for production.  As of June 30, 2014, there were no costs remaining in prepaid expenses and other current assets associated with these agreements.

Property_And_Equipment

Property And Equipment	6 Months Ended
	Jun. 30, 2014
Property And Equipment [Abstract]	'
Property And Equipment	'
	7. PROPERTY AND EQUIPMENT
	Property and equipment consisted of the following:
		June 30,		December 31,
		2014		2013
		(In thousands)
	Furniture and office equipment	$	2,823	$	2,823
	Laboratory and manufacturing equipment		29,495		29,493
	Computer equipment and software		71,802		70,976
	Leasehold improvements		117,149		117,233
	Buildings		17,872		17,872
	Construction in progress		424		368
		$	239,565	$	238,765
	Less accumulated depreciation		-126,109		-113,597
		$	113,456	$	125,168
	The buildings under our manufacturing facility leases must be restored to original condition upon lease termination. Accordingly, we have accrued the estimated costs of dismantlement and restoration associated with these obligations. The asset retirement obligations related to manufacturing facilities in Orange County, California (the “Orange County Facility”) and in Atlanta, Georgia (the “Atlanta Facility”) are included in “Long-term accrued liabilities” on the consolidated balance sheets.
	For further description of the facility leases refer to Note 9 – Financing Obligations and Note 13 – Commitments and Contingencies.
	Depreciation expense, including depreciation of assets acquired through capital leases, for the three and six months ended June 30, 2014 was $6.0 million and $12.5 million, respectively and for the three and six months ended June 30, 2013 was $7.9 million and $15.7 million, respectively.

Accrued_Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2014
Accrued Liabilities [Abstract]	'
Accrued Liabilities	'
	8. ACCRUED LIABILITIES
	Accrued liabilities consisted of the following:
		June 30,		December 31,
		2014		2013
		(In thousands)
	Deferred rent	$	6,499	$	6,886
	Inventory receipts		1,447		1,551
	Accrued consulting and other services		6,542		7,313
	Accrued clinical trials expense		2,827		3,157
	Accrued interest		8,170		8,225
	Accrued service fees and rebates		3,932		2,899
	Other accrued liabilities		6,513		3,588
		$	35,930	$	33,619

Financing_Obligations

Financing Obligations	6 Months Ended
	Jun. 30, 2014
Financing Obligations [Abstract]	'
Financing Obligations	'
	9. FINANCING OBLIGATIONS
	We lease the Orange County Facility and the Atlanta Facility, but were deemed owner of each of these manufacturing facilities during their construction periods under build-to-suit lease accounting. Upon completion of the facilities, we continued to be the deemed owner, and were required to capitalize building costs related to each facility. We therefore capitalized building costs of $6.7 million related to the Orange County Facility and $6.4 million related to the Atlanta Facility, and recorded corresponding financial obligations. We allocated the lease payments between the building and the land of each facility based upon estimated relative fair values. The portion of the lease payments associated with the building reduces the facility lease obligation, while the portion associated with the land is treated as payment of an operating lease obligation.
	The Orange County Facility lease obligation has an extended term of 15.5 years with an effective interest rate of 1.46%. The estimated term is based on an initial 10.5-year term and a 5-year renewal. The Orange County Facility lease may be renewed for up to an additional 20 years beyond the estimated 15.5-year term. The remaining facility lease obligation, based upon the estimated 15.5-year term, was $5.1 million as of June 30, 2014.
	The Atlanta Facility lease obligation has an extended term of 15.5 years with an effective interest rate of 3.37%. The estimated term is based on an initial 10.5-year term and a 5-year renewal. The Atlanta Facility lease may be renewed for up to an additional 20 years beyond the estimated 15.5-year term. The remaining facility lease obligation, based upon the estimated 15.5-year term, was $5.3 million as of June 30, 2014.

Convertible_Notes

Convertible Notes	6 Months Ended
	Jun. 30, 2014
Convertible Notes [Abstract]	'
Convertible Notes	'
	10. CONVERTIBLE NOTES
	2016 Notes
	On January 14, 2011, we entered into an underwriting agreement with J.P. Morgan Securities LLC (the “Underwriter”) relating to the offer and sale of $540 million aggregate principal amount of 2016 Notes. Under the terms of the underwriting agreement, we granted the Underwriter an option, exercisable within 30 days of the date of the agreement, to purchase up to an additional $80 million aggregate principal amount of 2016 Notes to cover overallotments. We issued $540 million in aggregate principal amount of 2016 Notes upon the closing of the offering on January 20, 2011. Net proceeds, after payment of underwriting fees and expenses, were $528.8 million. On January 31, 2011, the Underwriter exercised the overallotment option in full, and we closed on the sale of the additional $80 million in principal amount of 2016 Notes on February 3, 2011. Net proceeds from the exercise of the overallotment option, after payment of underwriting fees and expenses, were $78.3 million.
	On January 20, 2011, we entered into the First Supplemental Indenture with The Bank of New York Mellon Trust Company, N.A., as trustee, to our existing Base Indenture (together with the First Supplemental Indenture, the “2016 Indenture”), dated March 16, 2007. The 2016 Indenture sets forth the rights and provisions governing the 2016 Notes. Interest at 2.875% per annum is payable on the 2016 Notes semi-annually in arrears on January 15 and July 15 of each year. Record dates for payment of interest on the 2016 Notes are each January 1 and July 1. The maturity date of the 2016 Notes is January 15, 2016, unless earlier converted.
	The 2016 Notes are convertible at the option of the holder, and we may choose to satisfy conversions, if any, in cash, shares of our common stock, or a combination of cash and shares of our common stock, based on a conversion rate initially equal to 19.5160 shares of common stock per $1,000 principal amount of 2016 Notes, which is equivalent to an initial conversion price of $51.24 per share. The conversion rate will be increased under certain circumstances described in the 2016 Indenture; however, the number of shares of common stock issued upon conversion of a 2016 Note will not exceed 27.3224 per $1,000 principal amount of 2016 Notes, subject to adjustment in accordance with the 2016 Indenture. Should a holder exercise the conversion option during the next twelve-month period, it is our intention to satisfy the conversion with shares of common stock. Consequently, the 2016 Notes are classified as a long-term liability as of June 30, 2014 and December 31, 2013.
	The conversion rate will be adjusted upon the occurrence of certain events, including stock dividends or share splits, the issuance of rights, options or warrants, spin-offs or other distribution of property, cash dividends or distributions, or tender offers or exchange offers. We will not make an adjustment to the conversion rate for any transaction described above (other than share splits or share combinations) if each holder of 2016 Notes has the right to participate in such transaction at the same time and upon the same terms as holders of common stock, and solely as a result of holding 2016 Notes, without having to convert 2016 Notes, as if a number of shares of common stock were held equal to the applicable conversion rate multiplied by the principal amount of 2016 Notes held.
	If a “fundamental change,” as defined in the 2016 Indenture, occurs, holders of 2016 Notes may require us to repurchase all or a portion of their 2016 Notes for cash at a repurchase price equal to 100% of the principal amount of 2016 Notes to be repurchased, plus any accrued and unpaid interest and other amounts due thereon. However, if a fundamental change occurs and a holder elects to convert 2016 Notes, we will, under certain circumstances, increase the applicable conversion rate for 2016 Notes surrendered for conversion by a number of additional shares of common stock, based on the date on which the fundamental change occurs or becomes effective and the price paid per share of common stock in the fundamental change as specified in the 2016 Indenture. At our option, we will satisfy our conversion obligation with cash, shares of common stock or a combination of cash and shares, unless the consideration for common stock in any fundamental change is comprised entirely of cash, in which case the conversion obligation will be paid in cash. The number of additional shares of common stock was determined such that the fair value of the additional shares would be expected to approximate the fair value of the convertible option at the date of the fundamental change.
	In addition, we may from time to time increase the conversion rate, to the extent permitted by law, by any amount for any period of time if the period is at least 20 business days and we provide 15 business days prior written notice of such increase. We may increase the conversion rate if our Board of Directors determines that such increase would avoid or diminish United States federal income tax to holders of common stock in connection with a dividend or distribution. The 2016 Indenture contains customary covenants.
	The 2016 Notes are accounted for in accordance with FASB Accounting Standards Codification 470-20 (“ASC 470-20”), Debt with Conversion and Other Options, under which issuers of certain convertible debt instruments that may be settled entirely or partially in cash upon conversion are required to separately account for the liability (debt) and equity (conversion option) components of the instrument. The liability component of the 2016 Notes, as of the issuance date, was calculated by estimating the fair value of a similar liability issued at an 8.1% effective interest rate, which was determined by considering the rate of return investors would require in the Company’s debt structure. The amount of the equity component was calculated by deducting the fair value of the liability component from the principal amount of the 2016 Notes and resulted in a corresponding debt discount. The debt discount is being amortized as interest expense through the earlier of the maturity date of the 2016 Notes or the date of conversions, if any.
	The application of ASC 470-20 resulted in the initial recognition of $132.9 million as the debt discount recorded in additional paid-in capital for the 2016 Notes. The net carrying amount of the liability component, which is recorded as a long-term liability in the consolidated balance sheets, and the remaining unamortized debt discount were as follows:
		June 30,		December 31,
		2014		2013
		(In thousands)
	Aggregate principal amount of 2016 Notes	$	620,000	$	620,000
	Unamortized discount of the liability component		-46,865		-60,878
	Carrying amount of the liability component	$	573,135	$	559,122
	We incurred debt issuance costs of $12.9 million related to the 2016 Notes. In accordance with ASC 470-20, we allocated $10.1 million of debt issuance costs to the liability component of the 2016 Notes, and are amortizing these costs to interest expense through the earlier of the maturity date of the 2016 Notes or the date of conversions, if any. The remaining debt issuance costs of $2.8 million were allocated to the equity component of the 2016 Notes and recorded as an offset to additional paid-in capital.
	Amortization of the debt discount and debt issuance costs resulted in non-cash interest expense of $7.6 million and $15.1 million for the three and six months ended June 30, 2014, respectively, and $7.0 million and $13.9 million for the three and six months ended June 30, 2013, respectively. In addition, interest expense recognized on the 2.875%  stated coupon rate was $4.5 million for each of the three months ended June 30, 2014 and 2013, and $8.9 million for each of the six months ended June 30, 2014 and 2013.
	We have identified other embedded derivatives associated with the 2016 Notes. These embedded derivatives meet certain criteria and are therefore not required to be accounted for separately from the 2016 Notes.
	2014 Notes
	In 2007, an aggregate of $85.3 million of 2014 Notes was sold in a private placement to qualified institutional buyers. Proceeds from the offering, after deducting placement fees and expenses of $3.0 million, were $82.3 million. The 2014 Notes were issued at face principal amount and paid interest at 4.75% per annum on a semi-annual basis in arrears on June 15 and December 15 of each year. The maturity date of the 2014 Notes was June 15, 2014, at which time the 2014 Notes were repaid in full.
	As of December 31, 2013, the $27.7 million aggregate principal amount of 2014 Notes outstanding was classified as a current liability. We recorded interest expense, including the amortization of debt issuance costs, related to the 2014 Notes of $0.3 million during the three months ended June 30, 2014, $0.4 million during the three months ended June 30, 2013, and $0.7 million during each of the six months ended June 30, 2014 and 2013.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2014
Stock-Based Compensation [Abstract]	'
Stock-Based Compensation	'
	11. STOCK-BASED COMPENSATION
	Our equity-based employee incentive plans are described more fully in Note 12 in the 2013 Form 10-K, and in the Definitive Proxy Statement for the 2014 Annual Meeting of Stockholders. Our stock-based awards include non-qualified stock options, incentive stock options, restricted stock, restricted stock units and stock appreciation rights.
	We recorded stock-based compensation expense (contra expense) in the consolidated statements of operations as follows:
		Three Months Ended					Six Months Ended
		June 30,					June 30,
		2014			2013		2014		2013
		(In thousands)					(In thousands)
	Cost of revenue	$	114		$	106	$	-57	$	187
	Research and development		-658			1,363		-377		2,262
	Selling, general and administrative		1,846			2,094		-75		3,196
	Restructuring		-			1		-		9
		$	1,302		$	3,564	$	-509	$	5,654
	We have granted restricted stock awards and stock options with certain performance conditions to certain executive officers and key employees. At each reporting date, we evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon our assessment of accomplishing each performance provision or the occurrence of other events which may cause the awards or options to accelerate and vest. For the three and six months ended June 30, 2014 compensation expense related to awards and options with performance conditions was not material. For the three and six months ended June 30, 2013, we recognized $0.3 million and $0.5 million, respectively, of compensation expense related to awards and options with performance conditions.
	In the second quarter of 2013, we granted cash-settled stock appreciation rights with a two-year vest period to certain employees. These awards are classified as liabilities and are measured at fair value at each reporting date, with fair value being determined using the BSM model. For the three and six months ended June 30, 2014, we recognized $0.1 million stock-based compensation contra expense related to cash-settled stock appreciation rights. For the three and six months ended June 30, 2013, we recognized $0.2 million of compensation expense related to cash-settled stock appreciation rights. As of June 30, 2014, unrecognized compensation expense related to unvested cash-settled stock appreciation rights was not material. We expect to recognize the remaining compensation expense over a period of 0.9 years.
	In the first and second quarters of 2014 and 2013, we increased our estimated forfeiture rates based on historical data, resulting in cumulative catch-up adjustments to decrease stock-based compensation expense and net loss by $3.6 million and $5.8 million for the six months ended June 30, 2014 and 2013, respectively. These adjustments decreased basic and diluted net loss per share by $0.02 and $0.04 for the six months ended June 30, 2014 and 2013, respectively.
	The fair value of stock options was estimated at the date of grant using the BSM model with the following weighted average assumptions:
		Three Months Ended June 30,					Six Months Ended June 30,
		2014			2013		2014		2013
	Weighted average estimated fair value per share	$	1.52		$	2.75	$	2.01	$	3.17
	Weighted Average Assumptions
	Dividend yield (a)		0.0%			0.0%		0.0%		0.0%
	Expected volatility (b)		82%			85%		84%		85%
	Risk-free interest rate (c)		1.55%			0.84%		1.53%		0.86%
	Expected term (d)		5.0 years			5.0 years		5.0 years		5.0 years
		(a)		We have not paid dividends in the past and do not plan to pay dividends in the near future.
		(b)		The expected stock price volatility is based on the weighted average historical volatility of our stock.
		(c)		The risk-free interest rate is based on the implied yield available on United States Treasury zero-coupon issues with a term equal to the expected life of the award on the date of grant.
	(d)The expected term of options granted represents the estimated period of time until exercise and is based on the historical weighted average term of similar awards, giving consideration to the contractual terms, vesting schedules, expectations of future employee behavior and the terms of certain peer companies.
	The following summarizes stock option activity:
			Number of Shares			Weighted-Average Exercise Price per Share		Weighted-Average Remaining Contractual Life (in years)
	Outstanding at January 1, 2014		3,008,893		$	15.10
	Granted		481,995			4.42
	Exercised		-			-
	Forfeited and expired		-1,160,793			12.90
	Outstanding at June 30, 2014		2,330,095			14.15		6.90
	Options exercisable at June 30, 2014		1,448,383			17.00		6.20
	As of June 30, 2014 we had $1.1 million of unrecognized compensation expense related to unvested stock options, which we expect to recognize over a weighted-average period of 1.0 years.  The aggregate intrinsic value of options outstanding and options exercisable as of June 30, 2014 was not material.
	The following summarizes restricted stock award activity:
			Number of Shares			Weighted-Average Grant Date Fair Value
	Outstanding at January 1, 2014		3,919,972		$	6.94
	Granted		3,400,431			2.97
	Vested		-1,374,601			8.41
	Forfeited and expired		-1,278,096			4.46
	Outstanding at June 30, 2014		4,667,706			3.76
	As of June 30, 2014, we had $8.6 million of unrecognized compensation expense related to restricted stock awards, which we expect to recognize over a weighted-average period of 1.3 years.

Restructuring_Contract_Termina

Restructuring, Contract Termination And Advisory Costs	6 Months Ended
	Jun. 30, 2014
Restructuring, Contract Termination And Advisory Costs [Abstract]	'
Restructuring, Contract Termination Fees And Advisory Costs	'
	12. RESTRUCTURING, CONTRACT TERMINATION AND ADVISORY COSTS
	Advisory Costs
	In 2014, we worked with advisors on alternatives for a possible restructuring of our balance sheet. During the three and six months ended June 30, 2014, we recorded advisory charges of $3.1 million and $3.7 million, respectively, related to fees associated with seeking alternatives.
	Restructuring – 2013
	On November 12, 2013, we announced a restructuring of the Company and implemented additional cost reduction measures. As a result, during the six months ended June 30, 2014, we recorded restructuring charges of $1.0 million related to fees associated with implementing the restructuring plan. During the six months ended June 30, 2014, we recorded $0.2 million related to severance and other employee termination benefits, net of adjustments for termination benefits not used by employees and severance and termination benefits that will not be paid.  Restructuring initiatives were substantially complete as of June 30, 2014.
	Restructuring – 2012
	On July 30 2012, we announced that our Board of Directors had approved a strategic restructuring plan that included re-configuring our manufacturing model with the closure of our manufacturing facility in Morris Plains, New Jersey (the “New Jersey Facility”), restructuring administrative functions and strengthening commercial functions, which lowered our overall cost structure. The restructuring initiatives included a reduction in workforce of approximately 600 full-time and contractor positions. The employees affected by the workforce reduction were notified the week of September 17, 2012.
	On December 20, 2012, we announced the sale of the New Jersey Facility to Novartis Pharmaceuticals Corporation (“Novartis”) for $43.0 million. As part of the agreement with Novartis, approximately 100 employees at the facility who were previously included in the workforce reduction were offered jobs with Novartis.
	During the three and six months ended June 30, 2013, we recorded charges of $0.2 million and $1.4 million, respectively, related to severance and other termination benefits. These charges were offset by adjustments to reduce the restructuring liability by $0.9 million and $1.2 million for the three and six months ended June 30, 2013, respectively, related to termination benefits not used by employees and to severance and termination benefits that were not paid. In addition, we recorded restructuring charges of $0.6 million and $1.6 million during the three and six months ended June 30, 2013, respectively, related to relocation benefits offered to employees, expenses associated with the closure of the New Jersey Facility, contract termination expenses and other related expenses. We do not expect to incur additional restructuring charges related to the 2012 restructuring as the implementation of these initiatives is complete.
	Contract Termination – 2011
	On September 1, 2011 we provided written notice to GlaxoSmithKline LLC (“GSK”) of termination of a Development and Supply Agreement (the “GSK Agreement”) effective on October 31, 2011. We entered into the GSK Agreement for the commercial production and supply of the antigen used in the manufacture of PROVENGE. We exercised our right to terminate the GSK Agreement when, after unforeseen delays, GSK failed to complete the process implementation phase on or before September 1, 2011 pursuant to the terms of the GSK Agreement.
	Refer to Note 13 – Commitments and Contingencies, for discussion of a lawsuit filed in the Durham County Superior Court of North Carolina against the Company by GSK. We have accrued approximately $4.0 million in fees in connection with the termination of the GSK Agreement. This amount is included in “Restructuring,  contract termination and advisory liabilities” on the consolidated balance sheets as of June 30, 2014 and December 31, 2013. The ultimate financial impact of the lawsuit is not yet determinable. Therefore, no additional provision for loss has been recorded in the financial statements.
	The following is a rollforward of restructuring, contract termination and advisory liabilities:
		Restructuring, Contract Termination and Advisory Liabilities as of December 31, 2013		Charges, Net of Adjustments		Payments		Restructuring, Contract Termination  and Advisory Liabilities as of June 30, 2014
		(In thousands)
	Advisory costs:
	Advisory costs		—		3,738		-3,117		621
	2013 Restructuring:
	Severance and other termination benefits	$	4,362	$	217	$	-4,431	$	148
	Other associated costs		289		950		-1,153		86
	2012 Restructuring:
	Other associated costs		142		—		—		142
	2011 Restructuring:
	Contract termination costs		4,000		—		—		4,000
	Total	$	8,793	$	4,905	$	-8,701	$	4,997
	Total restructuring, contract termination and advisory charges of $4.9 million are included in “Restructuring, contract termination and advisory costs” on the consolidated statement of operations for the six months ended June 30, 2014.

Commitments_And_Contingencies

Commitments And Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies [Abstract]	'
Commitments And Contingencies	'
	13. COMMITMENTS AND CONTINGENCIES
	As previously disclosed, our 2016 Notes in an aggregate principal amount of $620 million mature on January 15, 2016. Our stock price is well below the $51.24 effective conversion price for the 2016 Notes, making it unlikely that the holders of the 2016 Notes will exercise their conversion right. As a result, we assume that, absent the execution of a transaction of the type described below, we will be required under the terms of the 2016 Notes to repay the full $620 million principal amount at maturity. Based on our currently anticipated operating results, however, and even assuming the realization of future expense reductions that we plan to make and product revenues that we forecast, there is a significant risk that, while we believe we have sufficient cash to meet our ordinary course obligations for at least the next twelve months, we will not be able to repay or refinance the 2016 Notes. Accordingly, we are currently considering alternatives to the repayment of the 2016 Notes in cash, including alternatives that could result in leaving our current stockholders with little or no financial ownership of Dendreon. Our Board of Directors will consider any strategic alternatives that might be presented by third parties, though there can be no guarantee that any such alternative will provide value for the Company’s stockholders.
	We have a supply agreement with Fujifilm Diosynth Biotechnologies (“Fujifilm”) covering the commercial production of the recombinant antigen used in the manufacture of PROVENGE. The second amendment to the supply agreement extended the term of the agreement through December 31, 2018. Unless terminated, the agreement will renew automatically thereafter for additional 5-year terms. The agreement may be terminated upon written notice by us or Fujifilm at least 24 months before the end of a renewal term or by either party in the event of an uncured material breach or default by the other party.
	As of June 30, 2014, we had remaining commitments with Fujifilm to purchase antigen not to exceed and most likely less than $6.7 million. We expect that payments on this commitment will continue through 2014.
	We have been self-insured since January 1, 2014 with regard to health and welfare claims up to $250,000 per person per year, above which third party insurance applies. A reserve of $1.4 million representing estimated reported losses, estimated unreported losses based on past experience modified for current trends, and estimated expenses for settling claims is included in accrued liabilities at June 30, 2014.  Actual losses may vary from the recorded reserves.  While we use what we believe are pertinent information and factors in determining the amount of reserves, future additions to the reserves may be necessary due to changes in the information and factors used.
	We have operating lease obligations related to two leases in Seattle, Washington which cover our principal corporate offices and research facility, a corporate office lease in Bridgewater, New Jersey, and the land portions of the Orange County Facility and the Atlanta Facility.
	In February 2011, we entered into a lease for office space of 179,656 square feet in Seattle, Washington with an initial lease term of five and a half years and one renewal term of two and a half years. In July 2012, we amended the lease to reduce the premises to 158,081 square feet. The related rent reduction took effect in November 2012. In April 2013, we amended the lease to further reduce the premises to 112,915 square feet. Rent payments related to the space relinquished in April 2013 cease effective October 2013 and August 2014. In addition, in April 2013 and November 2013, we subleased to two separate third parties 22,583 square feet each at these premises, commencing in May 2013 and December 2013, and continuing through the remaining lease term.
	In February 2011, we entered into a sublease for laboratory and office space of 97,365 square feet in Seattle, Washington. The lease term is for eight years. In July 2012, we entered into a lease for office space of 39,937 square feet in Bridgewater, New Jersey. The initial lease term is for ten years, with one renewal term of five years.
	In August 2009, we entered into an agreement to lease the Orange County Facility, comprising approximately 184,000 square feet, for use as a manufacturing facility following build-out. The initial lease term is ten and a half years, expiring in December 2019, with five renewal terms of five years each. In July 2009, we entered into an agreement to lease the Atlanta Facility, comprising approximately 156,000 square feet, for use as a manufacturing facility following build-out. The initial lease term is ten and a half years, with five renewal terms of five years each.
	We account for the Orange County Facility and the Atlanta Facility as assets with related facility lease obligations due to our significant investment in the build-out of the facilities. The lease payments are allocated to the building and land based on their estimated relative fair values. The portion of the lease related to land is treated as an operating lease. The portion of the lease related to the building is treated as a facility lease obligation as further discussed in Note 9 – Financing Obligations.
	As described in Note 5 – Inventory, for the year ended December 31, 2013, we recorded a charge of $46.2 million related to antigen inventory which no longer met quality specification and was not usable for commercial production, or which was determined to be likely to fail such quality specification. We have insurance coverage for up to $30.0 million for antigen losses of the type we believe we have sustained. We have filed an insurance claim to seek recovery for these losses. As of June 30, 2014, we have received $15.6 million in insurance proceeds related to this inventory claim and are pursing the remaining reimbursement from our insurance carrier. The $15.6 million recovery is included in “Inventory insurance recovery” on our consolidated statement of operations. Reimbursement of the remaining $14.4 million cannot be assured with certainty at this time. We believe no other antigen inventory was at risk of being out of quality specification at June 30, 2014.
	The Company and three former officers are named defendants in a securities action pending in the United States District Court for the Western District of Washington (the “District Court”) and brought by a group of individual investors who elected to opt out of a securities class action lawsuit that was settled in August 2013.  The pending action, filed May 16, 2013, is captioned Christoph Bolling, et al. v. Dendreon Corporation, et al., Case No. 2:13-cv-0872 JLR. Plaintiffs allege generally that the Company made various false or misleading statements between April 29, 2010 and August 3, 2011 concerning the Company, its finances, business operations and prospects with a focus on the market launch of PROVENGE and related forecasts concerning physician adoption, and revenue from sales of PROVENGE. Based on information provided informally by plaintiffs’ counsel, the plaintiff group, which totals approximately 30 persons, purports to have purchased approximately 250,000 shares of Dendreon common stock during the relevant period. The Bolling plaintiffs filed an amended complaint on July 16, 2013, alleging both violations of certain provisions of the federal Securities Exchange Act of 1934 and provisions of Washington state law and seeking unspecified damages.  In response to a motion by defendants, the federal claims were dismissed with leave to amend in January 2014.  On February 17, 2014, plaintiffs filed a Second Amended Complaint which defendants moved to dismiss on March 24, 2014. After briefing, the District Court, by order dated June 5, 2014, again dismissed the federal claims, but denied the motion as to the plaintiffs’ Washington state law claims for fraudulent and negligent misrepresentation.  The case is now in the discovery phase. We cannot predict the outcome of the litigation; however, the Company intends to continue defending against claims vigorously.
	The Company also is the subject of stockholder derivative complaints first filed in August 2011 generally arising out of the facts and circumstances that are alleged to underlie the previously settled securities action. . Derivative suits filed in the District Court were consolidated into a proceeding captioned In re Dendreon Corp. Derivative Litigation, Master Docket No. C 11-1345 JLR; others were filed in the Superior Court of Washington for King County and were consolidated into a proceeding captioned In re Dendreon Corporation Shareholder Derivative Litigation, Lead Case No. 11-2-29626-1 SEA. In addition, on June 22, 2012, another derivative action was filed in the Court of Chancery of the State of Delaware, captioned Herbert Silverberg, derivatively on behalf of Dendreon Corporation v. Mitchell H. Gold, et al., Case No. 7646-VCP. The various derivative complaints name as defendants various current and former officers and directors of the Company. While the complaints assert various legal theories of liability, the lawsuits generally allege that the defendants breached fiduciary duties owed to the Company in connection with the launch of PROVENGE and by purportedly subjecting the Company to potential liability for securities fraud. The complaints also include claims against certain defendants for supposed misappropriation of Company information and insider trading; the Silverberg complaint, asserts only this latter claim. After a formal mediation and further post-mediation negotiations, the parties to the various derivative actions reached a tentative settlement of the actions, the terms of which are set out in a Memorandum of Understanding dated as of July 18, 2014. The settlement is subject to final documentation and court approval.  We cannot predict whether the process of full settlement documentation and court approval will be successful.  In any event, the purported derivative lawsuits do not seek relief against the Company although the Company has certain indemnification obligations, including obligations to advance legal expense to the named defendants for defense of these lawsuits. Additionally, the Securities and Exchange Commission (“SEC”) is conducting a formal investigation, which we believe relates to some of the same issues raised in the securities and derivative actions. We are cooperating fully with the SEC investigation. The ultimate financial impact of these various proceedings, if any, is not yet determinable and therefore, no provision for loss, if any, has been recorded in the financial statements. With respect to all of the above-described proceedings, the Company has insurance that we believe affords coverage for much of the anticipated costs, subject to the policies’ terms and conditions.
	On March 7, 2014, a stockholder derivative complaint was filed in United States District Court for the District of Delaware.  The lawsuit, captioned Quintal v. Bayh, et al., No. 1:14-cv-00311-LPS, names as defendants both present and former members of the Company's Board of Directors.  Plaintiff's purported derivative complaint alleges that members of the Company’s Board of Directors violated the terms of the Company's 2009 Equity Incentive Plan by granting to non-employee directors shares of Company stock that vested immediately upon grant as part of the non-employee director's annual compensation package.  Defendants filed a motion to dismiss the complaint on April 14, 2014. The Court heard oral argument on Defendants' motion on July 29, 2014, and the motion is now under submission.  We cannot predict the outcome of the motion to dismiss or the timing of the action.  While the Company has certain indemnification obligations, including obligations to advance legal expense to the named defendants for defense of this lawsuit, the lawsuit does not seek monetary relief against the Company.
	The Company received notice in November 2011 of a lawsuit filed in the Durham County Superior Court of North Carolina (the “Court”) against the Company by GSK. The lawsuit purports claims for monies due and owing and breach of the Company’s obligations under the GSK Agreement terminated as of October 31, 2011. On April 9, 2013, GSK amended its complaint to add a claim for breach of North Carolina’s unfair and deceptive trade practices act. The Company does not believe the lawsuit has merit, filed a Counterclaim and Answer on January 6, 2012, and intends to defend its position vigorously. On March 11, 2014, the Court held oral argument on GSK’s motion for summary judgment on its breach of contract claim and the Company’s cross motion for summary judgment on GSK’s contract claim as well as its unfair and deceptive trade practices claim.  The Court has not yet issued a ruling on the parties’ cross motions.  On June 11 2014, GSK filed a separate motion for summary judgment on the Company’s counterclaims.  The Company intends to oppose that motion, which will be fully briefed by mid-August.  The Company has accrued approximately $4.0 million in fees in connection with the termination of the GSK Agreement. The ultimate financial impact of the lawsuit is not yet determinable. Therefore, no additional provision for loss has been recorded in the financial statements.

Business_Principles_Of_Consoli1

Business, Principles Of Consolidation And Basis Of Presentation (Policy)	6 Months Ended
	Jun. 30, 2014
Business, Principles Of Consolidation And Basis Of Presentation [Abstract]	'
Business	'
	Business
	Dendreon Corporation (referred to as “Dendreon,” the “Company,” “we,” “us,” or “our”), a Delaware corporation, is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. Our product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers.
	PROVENGE® (sipuleucel-T), is our first commercialized product approved by the United States Food and Drug Administration, and is a first-in-class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Commercial sale of PROVENGE began in May 2010. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second leading cause of cancer deaths in men in the United States. We own worldwide rights for PROVENGE.
Principles Of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Dendreon and its direct and indirect wholly-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation.
Basis Of Presentation	'
	Basis of Presentation
	The accompanying unaudited financial statements reflect, in the opinion of management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations and cash flows for each period presented in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from the accompanying statements. These interim financial statements should be read in conjunction with the audited financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2013 (the “2013 Form 10-K”). The accompanying financial information as of December 31, 2013 has been derived from the audited 2013 consolidated financial statements included in the 2013 Form 10-K. Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of results that may be expected for the year ending December 31, 2014, or any other future period.
Liquidity Risks And Uncertainties	'
	Liquidity Risks and Uncertainties
	Our 2016 Notes, as discussed in Note 10 below, have an aggregate principal amount of $620 million and mature on January 15, 2016. Our stock price is well below the $51.24 effective conversion price for the 2016 Notes, making it unlikely that the holders of the 2016 Notes will exercise their conversion right. As a result, we assume that, absent the execution of a transaction of the type described below, we will be required under the terms of the 2016 Notes to repay the full $620 million principal amount at maturity. Based on our currently anticipated operating results, however, and even assuming the realization of future expense reductions that we plan to make and product revenues that we forecast, there is a significant risk that, while we believe we have sufficient cash to meet our ordinary course obligations for at least the next twelve months, we will not be able to repay or refinance the 2016 Notes. Accordingly, we are currently considering alternatives to the repayment of the 2016 Notes in cash, including alternatives that could result in leaving our current stockholders with little or no financial ownership of Dendreon. Our Board of Directors will consider any strategic alternatives that might be presented by third parties, though there can be no guarantee that any such alternative will provide value for the Company’s stockholders.
	In addition, our business and operations are subject to various risks relating to our financial condition, some of which could result from concerns our stakeholders may have about our financial situation and others that could result if we were to pursue alternatives to the repayment of the 2016 Notes in cash.  These risks include, but are not limited to, the following:
		·	certain of our suppliers may attempt to cancel our contracts or restrict ordinary credit terms, require financial assurances of performance or refrain entirely from providing goods or services to us;
		·	our employees may become distracted from performance of their duties;
		·	physicians could cease to purchase and prescribe PROVENGE;
		·	we may have difficulty continuing to obtain and maintain contracts necessary to continue our operations and at affordable rates with competitive terms;
		·	we may have difficulty maintaining existing and building new relationships;
		·	and we may be unable to retain and motivate key executives and employees and we may have difficulty attracting new employees.
	As of June 30, 2014, our accumulated deficit was $2.3 billion and our net loss for six months ended June 30, 2014 was $51.7 million. We have incurred net losses as a result of research and development expenses, clinical trial expenses, contract manufacturing and facility expenses, costs associated with our commercial efforts on behalf of PROVENGE and general and administrative expenses in support of our operations and research efforts. The majority of our resources continue to be used in support of the commercialization of PROVENGE, including outside the United States. Even if we are able to successfully realize our current operating projections, we will likely be unable to repay or refinance the 2016 Notes when they mature. And in any event, we are unable to predict when our core business will break-even or become profitable, if at all. Even if we do produce revenues and achieve profitability, we may not be able to maintain or increase profitability, and our current stockholders may be left with little or no financial interest at such time.
Use Of Estimates	'
	Use of Estimates
	Our financial statements have been prepared in accordance with GAAP.  The preparation of these financial statements requires us to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, inventory, investments, fair values of assets, incurred but not reported medical insurance claims, income taxes, financing activities, accruals and other contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates.

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policy)	6 Months Ended
	Jun. 30, 2014
Summary Of Significant Accounting Policies [Abstract]	'
Revenue Recognition	'
	Revenue Recognition
	We recognize revenue primarily from the sale of PROVENGE. Revenue from the sale of PROVENGE is recorded net of product returns and estimated price discounts, including rebates and chargebacks offered pursuant to mandatory federal and state government programs and to members of Group Purchasing Organizations (“GPOs”) with which we have contracts. Revenue from sales of PROVENGE is recognized upon confirmed product delivery to and issuance of a product release form to the physician. Product returns are limited to those instances in which the physician receives the product but does not infuse the product prior to expiry, either due to timing or the failure of the product to meet specifications and pass site inspection. Due to the limited usable life of PROVENGE of approximately 18 hours from the completion of the manufacturing process to patient infusion, actual return information is known and credited against sales in the month incurred.
	PROVENGE sales are direct to physician; however, we have entered into distribution agreements with several credit-worthy third-party wholesalers (the “Wholesalers”) whereby we manufacture and ship the product direct to the physician and transfer the sale of PROVENGE to the Wholesalers. Under the distribution agreements, the Wholesalers assume all bad debt risk from the physician or institution; therefore no allowance for bad debt is recorded. Under the terms of the distribution agreements, our return policy allows for the return of product that has expired or has a defect prior to delivery, product that is damaged during delivery and product that cannot be infused because it does not otherwise meet specified requirements.
	Our product is subject to certain required pricing discounts via rebates and/or chargebacks pursuant to mandatory federal and state government programs and, accordingly, revenue recognition requires estimates of rebates and chargebacks.
	We have agreements with the Centers for Medicare and Medicaid Services (“CMS”) providing for a rebate on sales to eligible Medicaid patients. The physician purchases our product at full price, and then receives reimbursement from the applicable state. The state, in turn, invoices us for the amount of the Medicaid rebate. Estimated rebates payable under Medicaid are recognized in the same period that the related revenue is recognized, resulting in a reduction in product revenue, and are classified as other accrued liabilities until paid. Our estimate of rebates payable is based on historical claim information. Medicaid rebates were not material for each period presented.
	We also have agreements with the Public Health Service (“PHS”) and Federal Supply Schedule (“FSS”) customers, including the Department of Veteran Affairs and the Department of Defense, providing for a chargeback on sales to eligible providers. Chargebacks occur when a contracted physician purchases our product at fixed contract prices that are lower than the price we charge the Wholesalers. Each Wholesaler, in turn, charges us back for the difference between the price initially paid by the Wholesaler and the contract price paid to the Wholesaler by the physician. These chargebacks are estimated and recorded in the period that the related revenue is recognized, resulting in a reduction in product revenue and trade accounts receivable. The following is a roll forward of the chargebacks reserve associated with the PHS and FSS programs:
		Six Months Ended June 30,
		2014		2013
		(In thousands)
	Beginning balance, January 1	$	3,540	$	3,107
	Current provision related to sales made in current period		9,469		6,588
	Adjustments		-1,064		-1,575
	Payments/credits		-7,544		-5,425
	Balance at June 30	$	4,401	$	2,695
	We have entered into agreements with certain GPOs that contract for the purchase of PROVENGE on behalf of their members and provide contract administration services. Eligible members of the GPOs purchase PROVENGE at contracted prices through a chargeback. These chargebacks are estimated and recorded in the period that the related revenue is recognized, resulting in a reduction in product revenue and trade accounts receivable. The following is a roll forward of the chargebacks reserve associated with the GPO programs:
		Six Months Ended June 30,
		2014		2013
		(In thousands)
	Beginning balance, January 1	$	1,590	$	182
	Current provision related to sales made in current period		8,932		2,835
	Current provision related to sales made in prior periods		7		—
	Payments/credits		-9,200		-2,659
	Balance at June 30	$	1,329	$	358
	Eligible members of the GPOs may also be entitled to receive a rebate on eligible purchases of PROVENGE at the end of each quarter. Estimated rebates and administrative fees payable to GPOs are recognized in the same period that the related revenue is recognized, resulting in a reduction in product revenue, and are classified as other accrued liabilities until paid. Our estimate of rebates payable is based upon information we gather related to sales to eligible GPO members. The following is a roll forward of the accrued GPO rebates and administrative fees balance:
		Six Months Ended June 30,
		2014		2013
		(In thousands)
	Beginning balance, January 1	$	1,788	$	1,950
	Current provision related to sales made in current period		4,139		3,098
	Payments/credits		-3,518		-3,435
	Balance at June 30	$	2,409	$	1,613
Inventory	'
	Inventory
	Inventories are determined at the lower of cost or market value with cost determined under the specific identification method.
	We periodically evaluate our inventory for impairment by considering factors such as expiry, obsolescence and net realizable value. We review inventory for expiry risk by evaluating current and future product demand relative to inventory life. We expect to realize the carrying value of our inventory.
	In addition, we evaluate our inventory for impairment when events and circumstances indicate that our inventory may not meet the quality specifications required to be used in commercial production. If we determine it is likely that inventory does not meet quality specifications, we record an impairment of this inventory.
Restructuring Expenses	'
	Restructuring Expenses
	We record a liability for costs associated with an exit or disposal activity at fair value in the period in which the liability is incurred.  Employee termination benefits are accrued when the obligation is probable and estimable. Employee termination benefits are expensed at the date the employee is notified unless the employee must provide future service in excess of 60 days, in which case such benefits are expensed ratably over the future service period. For contract termination costs, we record a liability upon the later of the contract termination date or the date we cease using the rights conveyed by the contract.
Impairment Of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	We periodically evaluate the carrying value of long-lived assets to be held and used when events and circumstances indicate that the carrying amount of an asset may not be recovered. When evaluating long-lived assets for impairment, we compare the carrying value of the asset to the asset's estimated undiscounted future cash flows. Impairment is recorded if the estimated future cash flows are less than the carrying value of the asset. The impairment loss recognized, if any, is the excess of the asset’s carrying value over the fair value of the long-lived asset. The determination of fair value of the assets evaluated for impairment requires the use of judgmental assumptions surrounding the amount and timing of future cash flows and the highest and best use of the assets.
Accounting For Stock-Based Compensation	'
	Accounting for Stock-Based Compensation
	Stock-based compensation cost is estimated at the grant date based on the award’s fair value and is recognized on the accelerated method as expense over the requisite service period. The fair value of stock options granted and stock issued under the Employee Stock Purchase Plan is calculated using the Black-Scholes-Merton (“BSM”) option pricing model. The BSM model requires various judgmental assumptions regarding volatility and expected option life. If any of the assumptions used in the BSM model change significantly, stock-based compensation expense for new awards may differ materially from that recorded for existing awards.
	Restricted stock awards generally vest and are expensed over two- to four-year periods. We have granted restricted stock awards and options with certain performance conditions to certain executive officers and key employees. At each reporting date, we evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon our assessment of accomplishing each performance provision or the occurrence of other events which may have caused the awards or options to accelerate and vest.
	In the second quarter of 2013, we granted cash-settled stock appreciation rights with a two-year vest period to certain employees. These awards are classified as liabilities and are measured at fair value at each reporting date, with fair value being determined using the BSM model.
	Stock-based compensation accounting also requires the estimate of forfeiture rates. In the first and second quarters of 2014 and 2013, we increased our estimated forfeiture rates based on historical data, resulting in cumulative catch-up adjustments to decrease stock-based compensation expense and net loss by $3.6 million and $5.8 million for the six months ended June 30, 2014 and 2013, respectively. These adjustments decreased basic and diluted net loss per share by $0.02 and $0.04 for the six months ended June 30, 2014 and 2013, respectively.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding. The calculation of diluted net loss per share excludes all outstanding stock options, unvested restricted stock and shares issuable upon potential conversion of the 2.875% Convertible Senior Notes due 2016 (the “2016 Notes”) in the three and six months ended June 30, 2014 and 2013 and the 4.75% Convertible Senior Subordinated Notes due 2014 (the “2014 Notes”) in the three and six months ended June 30, 2013 because all such securities are anti-dilutive: accordingly, diluted net loss per shares is the same as basic net loss per share. For the three and six months ended June 30, 2014 and 2013, the computation of diluted net loss per share excluded 19.1 million shares and 23.3 million shares, respectively.
Comprehensive Loss	'
	Comprehensive Loss
	Comprehensive loss includes charges and credits to stockholders’ deficit that are not the result of transactions with stockholders. Comprehensive loss consisted of net loss plus changes in unrealized gain or loss on investments for the three and six months ended June 30, 2014 and 2013.
Loss Contingencies	'
	Loss Contingencies
	A loss contingency is recorded if it is probable that an asset has been impaired or a liability has been incurred and the amount of the loss can be reasonably estimated. We evaluate, among other factors, the probability of an unfavorable outcome and our ability to reasonably estimate the amount of the ultimate loss. Loss contingencies that we determine to be reasonably possible, but not probable, are disclosed but not recorded. Changes in these estimates could materially affect our financial position and results of operations.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update 2013-11 (“ASU 2013-11”), “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” This standard requires that an unrecognized tax benefit, or a portion of an unrecognized tax benefit be presented as a reduction of a deferred tax asset for an NOL carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions to this rule. If certain exception conditions exist, an entity should present an unrecognized tax benefit in the financial statements as a liability and should not net the unrecognized tax benefit with a deferred tax asset.  The adoption of ASU 2013-11 on January 1, 2014 did not have a material impact on our financial position, results of operations or cash flows.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers,” which supersedes the guidance in “Revenue Recognition (Topic 605)” and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. We are evaluating the new standard, but do not at this time expect this standard to have a material impact on our consolidated financial statements.
	For a more detailed listing of our significant accounting policies, see Note 2 of the consolidated financial statements included in the 2013 Form 10-K.

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Revenue, Major Customer [Line Items]	'
Schedule Of Accrued Rebates and Administrative Fees	'
		Six Months Ended June 30,
		2014		2013
		(In thousands)
	Beginning balance, January 1	$	1,788	$	1,950
	Current provision related to sales made in current period		4,139		3,098
	Payments/credits		-3,518		-3,435
	Balance at June 30	$	2,409	$	1,613
PSS And FSS Customers [Member]	'
Revenue, Major Customer [Line Items]	'
Schedule Of Chargebacks Reserve	'
		Six Months Ended June 30,
		2014		2013
		(In thousands)
	Beginning balance, January 1	$	3,540	$	3,107
	Current provision related to sales made in current period		9,469		6,588
	Adjustments		-1,064		-1,575
	Payments/credits		-7,544		-5,425
	Balance at June 30	$	4,401	$	2,695
Certain GPOs [Member]	'
Revenue, Major Customer [Line Items]	'
Schedule Of Chargebacks Reserve	'
		Six Months Ended June 30,
		2014		2013
		(In thousands)
	Beginning balance, January 1	$	1,590	$	182
	Current provision related to sales made in current period		8,932		2,835
	Current provision related to sales made in prior periods		7		—
	Payments/credits		-9,200		-2,659
	Balance at June 30	$	1,329	$	358

Investments_Tables

Investments (Tables)	6 Months Ended
	Jun. 30, 2014
Investments [Abstract]	'
Schedule Of Available For Sale Securities	'
		Cost or Amortized Cost		Fair Market Value
		(In thousands)
	June 30, 2014
	Due in one year or less	$	60,343	$	60,376
	Due after one year through two years		9,419		9,425
		$	69,762	$	69,801
	December 31, 2013
	Due in one year or less	$	87,027	$	87,092
	Due after one year through two years		19,805		19,819
		$	106,832	$	106,911
Short-Term And Long-Term Securities Available-For-Sale	'
		Cost or Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Market Value
		(In thousands)
	June 30, 2014
	Demand deposit	$	5,404	$	—	$	—	$	5,404
	Corporate debt securities		45,947		34		-1		45,980
	Government-sponsored enterprises		14,911		3		—		14,914
	U.S. Treasury notes		3,500		3		—		3,503
		$	69,762	$	40	$	-1	$	69,801
	December 31, 2013
	Demand deposit	$	5,404	$	—	$	—	$	5,404
	Corporate debt securities		64,867		59		-4		64,922
	Government-sponsored enterprises		13,064		12		—		13,076
	U.S. Treasury notes		23,497		12		—		23,509
		$	106,832	$	83	$	-4	$	106,911

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements [Abstract]	'
Schedule Of Financial Assets Measured At Fair Value On A Recurring Basis	'
	Description	Balance		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)
	Assets:	(In thousands)
	June 30, 2014
	Money market	$	61,901	$	61,901	$	—
	Corporate debt securities		45,980		—		45,980
	Government-sponsored enterprises		14,914		—		14,914
	U.S. Treasury notes		3,503		—		3,503
	Total financial assets		126,298	$	61,901	$	64,397
	Add: Cash		10,424
	Total cash, cash equivalents and investments	$	136,722
	December 31, 2013
	Money market	$	68,534	$	68,534	$	—
	Commercial paper		6,000		—		6,000
	Corporate debt securities		64,922		—		64,922
	Government-sponsored enterprises		13,076		—		13,076
	U.S. Treasury notes		23,509		—		23,509
	Total financial assets		176,041	$	68,534	$	107,507
	Add: Cash		23,400
	Total cash, cash equivalents and investments	$	199,441

Property_And_Equipment_Tables

Property And Equipment (Tables)	6 Months Ended
	Jun. 30, 2014
Property And Equipment [Abstract]	'
Schedule Of Components Of Property And Equipment	'
		June 30,		December 31,
		2014		2013
		(In thousands)
	Furniture and office equipment	$	2,823	$	2,823
	Laboratory and manufacturing equipment		29,495		29,493
	Computer equipment and software		71,802		70,976
	Leasehold improvements		117,149		117,233
	Buildings		17,872		17,872
	Construction in progress		424		368
		$	239,565	$	238,765
	Less accumulated depreciation		-126,109		-113,597
		$	113,456	$	125,168

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Accrued Liabilities [Abstract]	'
Schedule Of Components Of Accrued Liabilities	'
		June 30,		December 31,
		2014		2013
		(In thousands)
	Deferred rent	$	6,499	$	6,886
	Inventory receipts		1,447		1,551
	Accrued consulting and other services		6,542		7,313
	Accrued clinical trials expense		2,827		3,157
	Accrued interest		8,170		8,225
	Accrued service fees and rebates		3,932		2,899
	Other accrued liabilities		6,513		3,588
		$	35,930	$	33,619

Convertible_Notes_Tables

Convertible Notes (Tables)	6 Months Ended
	Jun. 30, 2014
Convertible Notes [Abstract]	'
Schedule Of Carrying Amount Of Liability Component And Remaining Unamortized Discount	'
		June 30,		December 31,
		2014		2013
		(In thousands)
	Aggregate principal amount of 2016 Notes	$	620,000	$	620,000
	Unamortized discount of the liability component		-46,865		-60,878
	Carrying amount of the liability component	$	573,135	$	559,122

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Stock-Based Compensation [Abstract]	'
Schedule Of Components Of Stock Compensation Expense	'
		Three Months Ended					Six Months Ended
		June 30,					June 30,
		2014			2013		2014		2013
		(In thousands)					(In thousands)
	Cost of revenue	$	114		$	106	$	-57	$	187
	Research and development		-658			1,363		-377		2,262
	Selling, general and administrative		1,846			2,094		-75		3,196
	Restructuring		-			1		-		9
		$	1,302		$	3,564	$	-509	$	5,654
Schedule Of Weighted Average Assumptions For Employee Stock Options	'
		Three Months Ended June 30,					Six Months Ended June 30,
		2014			2013		2014		2013
	Weighted average estimated fair value per share	$	1.52		$	2.75	$	2.01	$	3.17
	Weighted Average Assumptions
	Dividend yield (a)		0.0%			0.0%		0.0%		0.0%
	Expected volatility (b)		82%			85%		84%		85%
	Risk-free interest rate (c)		1.55%			0.84%		1.53%		0.86%
	Expected term (d)		5.0 years			5.0 years		5.0 years		5.0 years
		(a)		We have not paid dividends in the past and do not plan to pay dividends in the near future.
		(b)		The expected stock price volatility is based on the weighted average historical volatility of our stock.
		(c)		The risk-free interest rate is based on the implied yield available on United States Treasury zero-coupon issues with a term equal to the expected life of the award on the date of grant.
	(d)The expected term of options granted represents the estimated period of time until exercise and is based on the historical weighted average term of similar awards, giving consideration to the contractual terms, vesting schedules, expectations of future employee behavior and the terms of certain peer companies.
Summary Of Stock Option Activity	'
			Number of Shares			Weighted-Average Exercise Price per Share		Weighted-Average Remaining Contractual Life (in years)
	Outstanding at January 1, 2014		3,008,893		$	15.10
	Granted		481,995			4.42
	Exercised		-			-
	Forfeited and expired		-1,160,793			12.90
	Outstanding at June 30, 2014		2,330,095			14.15		6.90
	Options exercisable at June 30, 2014		1,448,383			17.00		6.20
Summary Of Restricted Stock Award Activity	'
			Number of Shares			Weighted-Average Grant Date Fair Value
	Outstanding at January 1, 2014		3,919,972		$	6.94
	Granted		3,400,431			2.97
	Vested		-1,374,601			8.41
	Forfeited and expired		-1,278,096			4.46
	Outstanding at June 30, 2014		4,667,706			3.76

Restructuring_Contract_Termina1

Restructuring, Contract Termination And Advisory Costs (Tables)	6 Months Ended
	Jun. 30, 2014
Restructuring, Contract Termination And Advisory Costs [Abstract]	'
Rollforward Of Restructuring, Contract Termination And Avisory Costs Liabilities	'
		Restructuring, Contract Termination and Advisory Liabilities as of December 31, 2013		Charges, Net of Adjustments		Payments		Restructuring, Contract Termination  and Advisory Liabilities as of June 30, 2014
		(In thousands)
	Advisory costs:
	Advisory costs		—		3,738		-3,117		621
	2013 Restructuring:
	Severance and other termination benefits	$	4,362	$	217	$	-4,431	$	148
	Other associated costs		289		950		-1,153		86
	2012 Restructuring:
	Other associated costs		142		—		—		142
	2011 Restructuring:
	Contract termination costs		4,000		—		—		4,000
	Total	$	8,793	$	4,905	$	-8,701	$	4,997

Business_Principles_Of_Consoli2

Business, Principles Of Consolidation And Basis Of Presentation (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Business, Principles Of Consolidation And Basis Of Presentation [Abstract]	'	'	'	'	'
Convertible senior notes, principal amount	$620,000,000	'	$620,000,000	'	$620,000,000
Convertible senior notes initial conversion price	$51.24	'	$51.24	'	'
Accumulated deficit	-2,302,807,000	'	-2,302,807,000	'	-2,251,154,000
Net income (loss)	($15,269,000)	($68,842,000)	($51,653,000)	($140,847,000)	'

Summary_Of_Significant_Account3

Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended			18 Months Ended		3 Months Ended	6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014
					Convertible Senior Notes Due 2014 [Member]	Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Stock Appreciation Rights [Member]	Minimum [Member]	Maximum [Member]
									Restricted Stock [Member]	Restricted Stock [Member]
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'	'	'
Product usable life	'	'	'18 hours	'	'	'	'	'	'	'
Future service period threshold for ratably expensing employee termination benefits	'	'	'60 days	'	'	'	'	'	'	'
Vesting period	'	'	'	'	'	'	'	'2 years	'2 years	'4 years
Cumulative catch-up adjustment to reduce stock-based compensation expense	'	'	$3.60	$5.80	'	'	'	'	'	'
Decrease to net loss per share	'	'	$0.02	$0.04	'	'	'	'	'	'
Interest rate of debt	'	'	'	'	4.75%	2.88%	2.88%	'	'	'
Convertible senior notes initial conversion price	$51.24	'	$51.24	'	'	'	'	'	'	'
Debt instrument maturity year	'	'	'	'	'2014	'2016	'	'	'	'
Shares excluded from net loss per share	19.1	23.3	19.1	23.3	'	'	'	'	'	'

Summary_Of_Significant_Account4

Summary Of Significant Accounting Policies (Schedule Of Chargebacks Reserve) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
PSS And FSS Customers [Member]	'	'
Revenue, Major Customer [Line Items]	'	'
Beginning balance, January 1	$3,540	$3,107
Current provision related to sales made in current period	9,469	6,588
Adjustments	-1,064	-1,575
Payments/credits	-7,544	-5,425
Balance at June 30	4,401	2,695
Certain GPOs [Member]	'	'
Revenue, Major Customer [Line Items]	'	'
Beginning balance, January 1	1,590	182
Current provision related to sales made in current period	8,932	2,835
Current provision related to sales made in prior periods	7	'
Payments/credits	-9,200	-2,659
Balance at June 30	$1,329	$358

Significant_Accounting_Policie

Significant Accounting Policies (Schedule Of Accrued Rebates and Administrative Fees) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Summary Of Significant Accounting Policies [Abstract]	'	'
Beginning balance, January 1	$1,788	$1,950
Current provision related to sales made in current period	4,139	3,098
Payments/credits	-3,518	-3,435
Balance at June 30	$2,409	$1,613

Investments_Narrative_Details

Investments (Narrative) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Investments [Abstract]	'	'
Investments securing letters of credit	$5.40	$5.40

Investments_Schedule_Of_Availa

Investments (Schedule Of Available-For-Sale Securities) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Investments [Abstract]	'	'
Due in one year or less, Cost or Amortized Cost	$60,343	$87,027
Due after one year through two years, Cost or Amortized Cost	9,419	19,805
Total debt securities available for sale, Cost or Amortized Cost	69,762	106,832
Due in one year or less, Fair Market Value	60,376	87,092
Due after one year through two years, Fair Market Value	9,425	19,819
Total debt securities available for sale, Fair Market Value	$69,801	$106,911

Investments_Schedule_Of_ShortT

Investments (Schedule Of Short-Term And Long-Term Securities Available-For-Sale) (Details) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	$69,762	$106,832
Gross Unrealized Gains	40	83
Gross Unrealized Losses	-1	-4
Total debt securities available for sale	69,801	106,911
Demand Deposit [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	5,404	5,404
Total debt securities available for sale	5,404	5,404
Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	45,947	64,867
Gross Unrealized Gains	34	59
Gross Unrealized Losses	-1	-4
Total debt securities available for sale	45,980	64,922
Government-Sponsored Enterprises [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	14,911	13,064
Gross Unrealized Gains	3	12
Total debt securities available for sale	14,914	13,076
U.S. Treasury Notes [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	3,500	23,497
Gross Unrealized Gains	3	12
Total debt securities available for sale	$3,503	$23,509

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (Convertible Senior Notes Due 2016 [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Convertible Senior Notes Due 2016 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Fair value of convertible notes	$427.80	$393.80

Fair_Value_Measurements_Schedu

Fair Value Measurements (Schedule Of Financial Assets Measured At Fair Value On A Recurring Basis) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	$126,298	$176,041
Add: Cash	10,424	23,400
Total cash, cash equivalents and investments	136,722	199,441
Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	61,901	68,534
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	64,397	107,507
Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	0	0
Money Market [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	61,901	68,534
Money Market [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	61,901	68,534
Money Market [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	'	'
Commercial Paper [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	'	6,000
Commercial Paper [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	'	6,000
Corporate Debt Securities [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	45,980	64,922
Corporate Debt Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	45,980	64,922
Government-Sponsored Enterprises [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	14,914	13,076
Government-Sponsored Enterprises [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	14,914	13,076
U.S. Treasury Notes [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	3,503	23,509
U.S. Treasury Notes [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	$3,503	$23,509

Inventory_Details

Inventory (Details) (USD $)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
Inventory [Abstract]	'	'	'
Raw materials	$70,000,000	$70,000,000	$54,300,000
Raw materials expected use	'	'2 years 7 months 6 days	'
Expense related to antigen inventory not useable for commercial production	'	'	46,200,000
Inventory impairment insurance coverage, amount	'	'	30,000,000
Inventory insurance recovery	15,566,000	15,566,000	'
Amount of loss remaining to be recovered	$14,400,000	$14,400,000	'

Prepaid_Expenses_And_Other_Cur1

Prepaid Expenses And Other Current Assets (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Prepaid Expenses And Other Current Assets [Abstract]	'
Costs associated with agreements to develop second source suppliers for materials and to qualify a contract manufacturer for production	$5.90

Property_And_Equipment_Narrati

Property And Equipment (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Property And Equipment [Abstract]	'	'	'	'
Depreciation expense	$6	$7.90	$12.50	$15.70

Property_And_Equipment_Schedul

Property And Equipment (Schedule Of Components Of Property And Equipment) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$239,565	$238,765
Less accumulated depreciation and amortization	-126,109	-113,597
Property and equipment, net	113,456	125,168
Furniture And Office Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	2,823	2,823
Laboratory And Manufacturing Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	29,495	29,493
Computer Equipment And Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	71,802	70,976
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	117,149	117,233
Buildings [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	17,872	17,872
Construction In Progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$424	$368

Accrued_Liabilities_Schedule_O

Accrued Liabilities (Schedule Of Components Of Accrued Liabilities) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]	'	'
Deferred rent	$6,499	$6,886
Inventory receipts	1,447	1,551
Accrued consulting and other services	6,542	7,313
Accrued clinical trials expense	2,827	3,157
Accrued interest	8,170	8,225
Accrued service fees and rebates	3,932	2,899
Other accrued liabilities	6,513	3,588
Accrued liabilities	$35,930	$33,619

Financing_Obligations_Details

Financing Obligations (Details) (USD $)	6 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Aug. 31, 2009	Jun. 30, 2014	Mar. 31, 2010
	Orange County Facility [Member]	Orange County Facility [Member]	Atlanta Facility [Member]	Atlanta Facility [Member]
Capital Leased Assets [Line Items]	'	'	'	'
Amount capitalized related to fair value of building owned	'	$6.70	'	$6.40
Extended term of lease, years	'15 years 6 months	'	'15 years 6 months	'
Effective interest rate of facility leases	1.46%	'	3.37%	'
Initial term of lease, years	'10 years 6 months	'	'10 years 6 months	'
Extension period of lease renewal term	'5 years	'	'5 years	'
Estimated term of facility lease	'15 years 6 months	'	'15 years 6 months	'
Additional renewal term, years	'20 years	'	'20 years	'
Aggregate remaining obligation of facility leases	$5.10	'	$5.30	'

Convertible_Notes_2016_Notes_D

Convertible Notes (2016 Notes) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Feb. 03, 2011	Jan. 20, 2011	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
			Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Maximum [Member]
									Equity Component [Member]	Liability Component [Member]	Convertible Senior Notes Due 2016 [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Face amount of notes issued	$620,000,000	$620,000,000	$80,000,000	$540,000,000	'	'	'	'	'	'	'
Debt instrument maturity year	'	'	'	'	'	'	'2016	'	'	'	'
Proceeds from issuance of convertible senior notes	'	'	78,300,000	528,800,000	'	'	'	'	'	'	'
Convertible senior notes initial conversion price	$51.24	'	'	'	$51.24	'	$51.24	'	'	'	'
Minimum number of days conversion rate increase must last	'	'	'	'	'	'	'20 days	'	'	'	'
Number of days written notice that is required prior to a conversion rate increase	'	'	'	'	'	'	'15 days	'	'	'	'
Convertible senior notes conversion ratio	'	'	'	'	'	'	0.019516	'	'	'	0.0273224
Debt instrument effective interest rate	'	'	'	'	8.10%	'	8.10%	'	'	'	'
Interest rate of debt	'	'	'	'	2.88%	'	2.88%	'	'	'	'
Payments of debt issuance costs	'	'	'	'	'	'	12,900,000	'	2,800,000	10,100,000	'
Carrying amount of the equity component	'	'	'	'	132,900,000	'	132,900,000	'	'	'	'
Convertible senior notes repurchase price	'	'	'	'	'	'	100.00%	'	'	'	'
Non-cash interest expense on debt discount and debt issuance costs	'	'	'	'	7,600,000	7,000,000	15,100,000	13,900,000	'	'	'
Interest on convertible senior notes based on stated coupon rate	'	'	'	'	$4,500,000	$4,500,000	$8,900,000	$8,900,000	'	'	'

Convertible_Notes_2014_Notes_D

Convertible Notes (2014 Notes) (Details) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2007	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Debt Instrument [Line Items]	'	'	'	'	'	'
Face amount of notes issued	'	$620,000,000	'	$620,000,000	'	$620,000,000
Convertible senior notes initial conversion price	'	$51.24	'	$51.24	'	'
Convertible senior subordinated notes due 2014	'	'	'	'	'	27,685,000
Convertible Senior Notes Due 2014 [Member]	'	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'	'
Face amount of notes issued	85,300,000	'	'	'	'	'
Payments of debt issuance costs	3,000,000	'	'	'	'	'
Proceeds from issuance of convertible senior notes	82,300,000	'	'	'	'	'
Interest rate of debt	4.75%	'	'	'	'	'
Debt instrument maturity year	'	'	'	'2014	'	'
Convertible senior subordinated notes due 2014	'	'	'	'	'	27,700,000
Interest on convertible senior notes based on stated coupon rate	'	$300,000	$400,000	$700,000	$700,000	'

Convertible_Notes_Schedule_Of_

Convertible Notes (Schedule Of Carrying Amount Of Liability Component And Remaining Unamortized Discount) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Convertible Notes [Abstract]	'	'
Aggregate principal amount of 2016 Notes	$620,000,000	$620,000,000
Unamortized discount of the liability component	-46,865,000	-60,878,000
Carrying amount of the liability component	$573,135,000	$559,122,000

StockBased_Compensation_Narrat

Stock-Based Compensation (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	$1,302,000	$3,564,000	($509,000)	$5,654,000
Cumulative catch-up adjustment to reduce stock-based compensation expense	'	'	3,600,000	5,800,000
Decrease to net loss per share	'	'	$0.02	$0.04
Restricted Stock [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized stock compensation expense related to unvested stock options	8,600,000	'	8,600,000	'
Weighted average period over which unrecognized compensation is expected to be recognized related to stock options	'	'	'1 year 3 months 18 days	'
Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized stock compensation expense related to unvested stock options	1,100,000	'	1,100,000	'
Weighted average period over which unrecognized compensation is expected to be recognized related to stock options	'	'	'1 year	'
Performance Shares [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	'	300,000	'	500,000
Cash-Settled Stock Appreciation Rights [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted average period over which unrecognized compensation is expected to be recognized related to stock options	'	'	'10 months 24 days	'
Vesting period	'	'	'2 years	'
Stock-based compensation expense	$100,000	$200,000	$100,000	$200,000

StockBased_Compensation_Schedu

Stock-Based Compensation (Schedule Of Components Of Stock Compensation Expense) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock compensation expense	$1,302	$3,564	($509)	$5,654
Cost Of Product Revenue [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock compensation expense	114	106	-57	187
Research And Development [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock compensation expense	-658	1,363	-377	2,262
Selling, General And Administrative [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock compensation expense	1,846	2,094	-75	3,196
Restructuring [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock compensation expense	'	$1	'	$9

StockBased_Compensation_Schedu1

Stock-Based Compensation (Schedule Of Weighted Average Assumptions For Employee Stock Options) (Details) (Stock Options [Member], USD $)	3 Months Ended				6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
Stock Options [Member]	'		'		'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'		'		'
Weighted average estimated fair value per share	$1.52		$2.75		$2.01		$3.17
Dividend yield	0.00%	[1]	0.00%	[1]	0.00%	[1]	0.00%	[1]
Expected volatility	82.00%	[2]	85.00%	[2]	84.00%	[2]	85.00%	[2]
Risk-free interest rate	1.55%	[3]	0.84%	[3]	1.53%	[3]	0.86%	[3]
Expected term (in years)	'5 years	[4]	'5 years	[4]	'5 years	[4]	'5 years	[4]
[1]	We have not paid dividends in the past and do not plan to pay dividends in the near future.
[2]	The expected stock price volatility is based on the weighted average historical volatility of our stock.
[3]	The risk-free interest rate is based on the implied yield available on United States Treasury zero-coupon issues with a term equal to the expected life of the award on the date of grant.
[4]	The expected term of options granted represents the estimated period of time until exercise and is based on the historical weighted average term of similar awards, giving consideration to the contractual terms, vesting schedules, expectations of future employee behavior and the terms of certain peer companies

StockBased_Compensation_Summar

Stock-Based Compensation (Summary Of Stock Option Activity) (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Stock-Based Compensation [Abstract]	'
Outstanding at January 1, 2014	3,008,893
Granted	481,995
Exercised	'
Forfeited and expired	-1,160,793
Outstanding at June 30, 2014	2,330,095
Options exercisable at June 30, 2014	1,448,383
Weighted-Average Exercise Price per Share, Outstanding at January 1, 2014	$15.10
Weighted-Average Exercise Price per Share, Granted	$4.42
Weighted-Average Exercise Price per Share, Exercised	'
Weighted-Average Exercise Price per Share, Forfeited and expired	$12.90
Weighted-Average Exercise Price per Share, Outstanding at June 30, 2014	$14.15
Weighted-Average Exercise Price per Share, Options exercisable at June 30, 2014	$17
Outstanding at June 30, 2014 Weighted Average Remaining Contractual Life (in years)	'6 years 10 months 24 days
Exercisable at June 30, 2014 Weighted Average Remaining Contractual Life (in years)	'6 years 2 months 12 days

StockBased_Compensation_Summar1

Stock-Based Compensation (Summary Of Restricted Stock Award Activity) (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Stock-Based Compensation [Abstract]	'
Outstanding at January 1, 2014	3,919,972
Granted	3,400,431
Vested	-1,374,601
Forfeited and expired	-1,278,096
Outstanding at June 30, 2014	4,667,706
Weighted-Average Grant Date Fair Value, Outstanding at January 1, 2014	$6.94
Weighted-Average Grant Date Fair Value, Granted	$2.97
Weighted-Average Grant Date Fair Value, Vested	$8.41
Weighted-Average Grant Date Fair Value, Forfeited and expired	$4.46
Weighted-Average Grant Date Fair Value, Outstanding at June 30, 2014	$3.76

Restructuring_Contract_Termina2

Restructuring, Contract Termination And Advisory Costs (Narrative) (Details) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended		1 Months Ended		6 Months Ended
	Jul. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
	employee					Novartis [Member]	Agreement With GSK [Member]	Associated With Implementing Restructuring Plan [Member]	Severance And Other Related Benefits [Member]
						employee
Restructuring, Contract Termination And Advisory Costs [Line Items]	'	'	'	'	'	'	'	'	'
Reduction in workforce	600	'	'	'	'	'	'	'	'
Number of eliminated employees who were offerred positions with buyer of facility	'	'	'	'	'	100	'	'	'
Advisory costs	'	$3,100,000	'	$3,700,000	'	'	'	'	'
Restructuring, contract termination and other related expenses	'	'	600,000	'	1,600,000	'	'	1,000,000	200,000
Proceeds from sale of facility	'	'	'	'	'	43,000,000	'	'	'
Charge for severance and other related termination benefits	'	'	200,000	'	1,400,000	'	'	'	'
Adjustment to reduce restructuring liability	'	'	900,000	'	1,200,000	'	'	'	'
Cancellation fee under development and supply agreement	'	4,000,000	'	4,000,000	'	'	4,000,000	'	'
Restructuring, contract termination and advisory costs	'	$3,059,000	($304,000)	$4,905,000	$1,656,000	'	'	'	'

Restructuring_Contract_Termina3

Restructuring, Contract Termination And Advisory Costs (Rollforward Of Restructuring Liabilities) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Restructuring, Contract Termination And Advisory Costs [Line Items]	'	'	'	'	'
Restructuring, Contract Termination and Advisory Liabilities at end of period	$4,997	'	$4,997	'	$8,793
Charges, Net Of Adjustments	3,059	-304	4,905	1,656	'
Payments	'	'	-8,701	'	'
Restructuring, Contract Termination and Advisory Liabilities	4,997	'	4,997	'	8,793
Advisory Costs [Member]	'	'	'	'	'
Restructuring, Contract Termination And Advisory Costs [Line Items]	'	'	'	'	'
Restructuring, Contract Termination and Advisory Liabilities at end of period	621	'	621	'	'
Charges, Net Of Adjustments	'	'	3,738	'	'
Payments	'	'	-3,117	'	'
Restructuring, Contract Termination and Advisory Liabilities	621	'	621	'	'
2013 Restructuring [Member] | Severance And Other Termination Benefits [Member]	'	'	'	'	'
Restructuring, Contract Termination And Advisory Costs [Line Items]	'	'	'	'	'
Restructuring, Contract Termination and Advisory Liabilities at end of period	148	'	148	'	4,362
Charges, Net Of Adjustments	'	'	217	'	'
Payments	'	'	-4,431	'	'
Restructuring, Contract Termination and Advisory Liabilities	148	'	148	'	4,362
2013 Restructuring [Member] | Other Associated Costs [Member]	'	'	'	'	'
Restructuring, Contract Termination And Advisory Costs [Line Items]	'	'	'	'	'
Restructuring, Contract Termination and Advisory Liabilities at end of period	86	'	86	'	289
Charges, Net Of Adjustments	'	'	950	'	'
Payments	'	'	-1,153	'	'
Restructuring, Contract Termination and Advisory Liabilities	86	'	86	'	289
2012 Restructuring [Member] | Other Associated Costs [Member]	'	'	'	'	'
Restructuring, Contract Termination And Advisory Costs [Line Items]	'	'	'	'	'
Restructuring, Contract Termination and Advisory Liabilities at end of period	142	'	142	'	142
Restructuring, Contract Termination and Advisory Liabilities	142	'	142	'	142
2011 Restructuring [Member] | Contract Termination Costs [Member]	'	'	'	'	'
Restructuring, Contract Termination And Advisory Costs [Line Items]	'	'	'	'	'
Restructuring, Contract Termination and Advisory Liabilities at end of period	4,000	'	4,000	'	4,000
Restructuring, Contract Termination and Advisory Liabilities	$4,000	'	$4,000	'	$4,000

Commitments_And_Contingencies_

Commitments And Contingencies (Details) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

Share data in Thousands, except Per Share data, unless otherwise specified

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Apr. 30, 2013

Jul. 31, 2012

Feb. 28, 2011

Feb. 28, 2011

Jul. 31, 2012

Aug. 31, 2009

Jul. 31, 2009

Jun. 30, 2014

defendant

Uninsured Risk [Member]

FujiFilm [Member]

Seattle Lease [Member]

Seattle Lease [Member]

Seattle Lease [Member]

Seattle Sublease [Member]

Bridgewater Space [Member]

Orange County Facility [Member]

Atlanta Facility [Member]

2013 Agreements [Member]

plaintiff

sqft

sqft

item

sqft

item

sqft

item

FujiFilm [Member]

sqft

sqft

item

sqft

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible senior notes, principal amount

$620,000,000

$620,000,000

$620,000,000

'

'

'

'

'

'

'

'

'

'

Convertible senior notes initial conversion price

$51.24

$51.24

'

'

'

'

'

'

'

'

'

'

'

Renewal term of supply agreement

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

Termination notice period of supply agreement

'

'

'

'

'24 months

'

'

'

'

'

'

'

'

Purchase commitment

'

'

'

'

'

'

'

'

'

'

'

'

6,700,000

Maximum coverage per incident

'

250,000

'

'

'

'

'

'

'

'

'

'

'

Self-Insurance Reserve

'

'

'

1,400,000

'

'

'

'

'

'

'

'

'

Expense related to antigen inventory not useable for commercial production

'

'

46,200,000

'

'

'

'

'

'

'

'

'

'

Inventory impairment insurance coverage, amount

'

'

30,000,000

'

'

'

'

'

'

'

'

'

'

Inventory insurance recovery

15,566,000

15,566,000

'

'

'

'

'

'

'

'

'

'

'

Inventory insurance, amount of loss remaining to be recovered

14,400,000

14,400,000

'

'

'

'

'

'

'

'

'

'

'

Rentable space under lease agreement, in square feet

'

'

'

'

'

112,915

158,081

179,656

97,365

39,937

184,000

156,000

'

Additional space subleased, in square feet

'

'

'

'

'

22,583

'

'

'

'

'

'

'

Term of lease, years

'

'

'

'

'

'

'

'5 years 6 months

'8 years

'10 years

'10 years 6 months

'10 years 6 months

'

Number of renewal terms

'

'

'

'

'

'

'

1

'

1

5

5

'

Renewal term, years

'

'

'

'

'

'

'

'2 years 6 months

'

'5 years

'5 years

'5 years

'

Expected cancellation fees under the Development and Supply Agreement

$4,000,000

$4,000,000

'

'

'

'

'

'

'

'

'

'

'

Number of former officers who are named defendants

'

3

'

'

'

'

'

'

'

'

'

'

'

Number of persons in plaintiff group

'

30

'

'

'

'

'

'

'

'

'

'

'

Common stock shares purchased by plaintiff group

'

250

'

'

'

'

'

'

'

'

'

'

'